Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine

被引：10
|
作者：
Kelly, DL [1 ]
Kreyenbuhl, J [1 ]
Love, RC [1 ]
Van-Duong, Q [1 ]
Conley, RR [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
来源：
JOURNAL OF CLINICAL PSYCHIATRY | 2003年 / 64卷 / 09期
关键词：
D O I：
10.4088/JCP.v64n0921f
中图分类号：
B849 [应用心理学];
学科分类号：
040203 ;
摘要：
引用
收藏
页码：1133 / 1134
页数：2
相关论文
共 50 条
  • [11] Comparison of metabolic parameters among patients of schizophrenia on treatment with Olanzapine and Risperidone
    Singh, Archana
    Tomar, Abhay Singh
    Khess, C. R. J.
    Munda, Sanjay
    Siddiqui, Aleem
    Shivani
    INDIAN JOURNAL OF PSYCHIATRY, 2020, 62 : S96 - S96
  • [12] Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up
    Attux, Cecilia
    Quintana, Maria Ines
    Chaves, Ana Cristina
    REVISTA BRASILEIRA DE PSIQUIATRIA, 2007, 29 (04) : 346 - 349
  • [13] Six-Month Lorcaserin Administration Decreases Body Weight and Improves Cardiometabolic Parameters
    Tuccinardi, Dario
    Farr, Olivia
    Upadhyay, Jagriti
    Oussaada, Sabrina
    Mathew, Hannah
    Paschou, Stavroula
    Koniaris, Anastasia
    Mantzoros, Christos
    DIABETES, 2017, 66 : LB88 - LB88
  • [14] Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics
    Wasserman, James I.
    Barry, Rebecca J.
    Bradford, Lisa
    Delva, Nicholas J.
    Beninger, Richard J.
    PSYCHOPHARMACOLOGY, 2012, 222 (01) : 173 - 183
  • [15] Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics
    James I. Wasserman
    Rebecca J. Barry
    Lisa Bradford
    Nicholas J. Delva
    Richard J. Beninger
    Psychopharmacology, 2012, 222 : 173 - 183
  • [16] COST-EFFECTIVE ANALYSIS OF CLOZAPINE COMPARED WITH OLANZAPINE, QUETIAPINE, AND RISPERIDONE IN THE MANAGEMENT OF PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA
    Ndebele, N.
    VALUE IN HEALTH, 2016, 19 (03) : A183 - A183
  • [17] The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone
    Lee, Nam Young
    Kim, Se Hyun
    Jung, Dong Chung
    Kim, Eun Young
    Yu, Han Young
    Sung, Ki Hye
    Kang, Ung Gu
    Ahn, Yong Min
    Kim, Yong Sik
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (05): : 1273 - 1278
  • [18] A six-month, double-blind, controlled trial in schizophrenic patients comparing amisulpride and olanzapine
    Mortimer, A
    Rein, W
    Fleurot, O
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S334 - S334
  • [19] PET imaging of dopamine D1 and D2 receptors in patients treated with clozapine, olanzapine, quetiapine, or risperidone
    Tauscher, J
    Hussain, T
    Agid, O
    Barsoum, P
    Hussey, D
    Wilson, AA
    Houle, S
    Zipursky, RB
    Kapur, S
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 246 - 246
  • [20] Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    McEvoy, JP
    Lieberman, JA
    Stroup, TS
    Davis, SM
    Meltzer, HY
    Rosenheck, RA
    Swartz, MS
    Perkins, DO
    Keefe, RSE
    Davis, CE
    Severe, J
    Hsiao, JK
    AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (04): : 600 - 610
12345